Hans Arwidsson
Chief Executive Officer bij EUROCINE VACCINES AB
Profiel
Hans Arwidsson is currently the President, Chief Executive Officer & Director at Eurocine Vaccines AB.
He is also the Chairman at Spago Nanomedical AB.
Additionally, he holds positions as a Director at Healthy Bizniz Europe AB and Eurocince Securities AB.
In the past, Dr. Arwidsson served as the Chief Executive Officer of Biosergen AS from 2004 to 2007.
He was also the Chief Executive Officer of Lipocore Holding AB in 2003.
Furthermore, he held director positions at Xspray Pharma AB and Nanexa AB from 2001 to 2003 and in 2016 to 2017 respectively.
Prior to that, he worked at AstraZeneca AB as a New Product Manager-Operations in 2001 and as the Vice President-Business Development at Astra Pharmaceuticals AB.
Dr. Arwidsson obtained an MBA from Stockholm School of Economics in 1996.
He also holds a graduate degree from the University of Uppsala and a doctorate degree from the same university in 1991.
Actieve functies van Hans Arwidsson
| Bedrijven | Functie | Begin |
|---|---|---|
| EUROCINE VACCINES AB | Chief Executive Officer | 01-01-2004 |
| SPAGO NANOMEDICAL AB | Chairman | 10-05-2023 |
| Healthy Bizniz Europe AB | Director/Board Member | - |
Eurocince Securities AB
 Eurocince Securities AB Real Estate DevelopmentFinance Eurocince Securities AB is a Swedish company that manages fixed and movable property. The private company is based in Stockholm, Sweden. | Director/Board Member | - |
Eerdere bekende functies van Hans Arwidsson
| Bedrijven | Functie | Einde |
|---|---|---|
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Chief Executive Officer | 01-01-2007 |
| Lipocore Holding AB | Chief Executive Officer | 01-01-2003 |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | 01-01-2001 |
| NANEXA AB | Chairman | - |
| XSPRAY PHARMA AB | Director/Board Member | - |
Opleiding van Hans Arwidsson
| Stockholm School of Economics | Masters Business Admin |
| University of Uppsala | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| EUROCINE VACCINES AB | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| NANEXA AB | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| Astra Pharmaceuticals AB | |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
| Healthy Bizniz Europe AB | |
| Lipocore Holding AB | |
Eurocince Securities AB
Eurocince Securities AB Real Estate DevelopmentFinance Eurocince Securities AB is a Swedish company that manages fixed and movable property. The private company is based in Stockholm, Sweden. | Finance |
